Epic was founded by Stanley Qi, a renowned bioengineer and named co-inventor on the CRISPR patent held by the University of California. The company’s mission is to develop a new class of genetic medicines that act on the epigenome, a naturally occurring mechanism that determines which genes are expressed and at what levels.

The company announced its launch and Series A financing of $55 million in July 2022.